InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (7 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
7
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by MacLean Michael F, Chief Financial Officer. Officer active across 1 company, notably Avidity Biosciences, Inc.. Aggregated, 15 reports have been recorded. Breakdown: 0 buy · 7 sells. Total volume traded: €4m. Activity tracked since 20 January 2023. The latest transaction was disclosed on 6 August 2025 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations15 total
30,914 shares@ US$42.726450.0% of flowCommon StockSEC:0001599901-25-000161
30,914 shares@ US$42.72640.50% mcap50.0% of flowCommon StockSEC:0001599901-25-000161:0
7,935 shares@ US$31.05543.9% of flowCommon StockSEC:0001599901-25-000069:0
1,622 shares@ US$28.59290.8% of flowCommon StockSEC:0001599901-25-000041:0
25,000 shares0Common StockSEC:0001599901-25-000023:0
11,151 shares@ US$32.665.9% of flowCommon StockSEC:0001599901-24-000206:0
27,262 shares@ US$46.218819.8% of flowCommon StockSEC:0001599901-24-000188:0
25,000 shares0Common StockSEC:0001599901-24-000156:0
25,000 shares0Common StockSEC:0001599901-24-000110:0
104,245 shares@ US$8.8214.6% of flowCommon StockSEC:0001599901-24-000101:0
75,000 shares@ US$8.8210.5% of flowCommon StockSEC:0000950170-24-061258:0
40,000 shares@ US$8.825.5% of flowCommon StockSEC:0001599901-24-000044:0
22,500 shares0Common StockSEC:0001599901-24-000008:0
1,616 shares@ US$10.130.3% of flowCommon StockSEC:0001599901-24-000008:1
18,500 shares0Common StockSEC:0001209191-23-004756:0
15 of 15 declarations
About MacLean Michael F
Michael F. MacLean is the Chief Financial Officer of Avidity Biosciences, Inc. In this role, he oversees the financial operations of the company, including financial planning, risk management, and financial reporting. His expertise contributes to the financial health and growth of the company.
